Interactions between Myc and MondoA transcription factors in metabolism and tumourigenesis

British Journal of Cancer

Volumn 113, Issue 11, 2015, Pages 1529-1533

  Wilde, Blake R ^a   Ayer, Donald E ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

cancer metabolism; MondoA; Myc; transcription; tumourigenesis; TXNIP

Indexed keywords

B RAF KINASE; MAX PROTEIN; MYC PROTEIN; THIOREDOXIN INTERACTING PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MONDOA; UNCLASSIFIED DRUG; VEMURAFENIB; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; CARRIER PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MONDOA PROTEIN, HUMAN; TXNIP PROTEIN, HUMAN;

AEROBIC METABOLISM; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CELLULAR STRESS RESPONSE; DNA BINDING; GENE EXPRESSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; MELANOMA; METABOLISM; NEUROBLASTOMA; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION; TRIPLE NEGATIVE BREAST CANCER; GENETICS;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CARCINOGENESIS; CARRIER PROTEINS; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MELANOMA; NEUROBLASTOMA; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTION FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84949319712     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.360     Document Type: Article

References (29)

1. Allen A, Gill K, Hoehn D, Sulis M, Bhagat G, Alobeid B. (2014). C-myc protein expression in B-cell acute lymphoblastic leukemia, prognostic significance? Leuk Res 38: 1061-1066.
2. Carroll PA, Diolaiti D, Mcferrin L, Gu H, Djukovic D, Du J, Cheng PF, Anderson S, Ulrich M, Hurley JB, Raftery D, Ayer DE, Eisenman RN. (2015). Deregulated Myc requires MondoA/Mlx for metabolic reprogramming and tumorigenesis. Cancer Cell 27: 271-285.
3. Chen JL, Merl D, Peterson CW, Wu J, Liu PY, Yin H, Muoio DM, Ayer DE, West M, Chi JT. (2010). Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA. PLoS Genet 6: e1001093.
4. Dang CV. (2012). Links between metabolism and cancer. Genes Dev 26: 877-890.
5. Dang CV. (2012). MYC on the path to cancer. Cell 149: 22-35.
6. Eilers M, Eisenman RN. (2008). Myc's broad reach. Genes Dev 22: 2755-2766.
7. Elgort MG, O'Shea JM, Jiang Y, Ayer DE. (2010). Transcriptional and translational downregulation of thioredoxin interacting protein is required for metabolic reprogramming during G1. Genes Cancer 1: 893-907.
8. Foulkes WD, Smith IE, Reis-Filho JS. (2010). Triple-negative breast cancer. N Engl J Med 363: 1938-1948.
9. Hernandez-Davies JE, Tran TQ, Reid MA, Rosales KR, Lowman XH, Pan M, Moriceau G, Yang Y, Wu J, Lo RS, Kong M. (2015). Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. J Transl Med 13: 210.
10. Hurlin PJ, Huang J. (2006). The MAX-interacting transcription factor network. Semin Cancer Biol 16: 265-274.
11. Iritani BM, Delrow J, Grandori C, Gomez I, Klacking M, Carlos LS, Eisenman RN. (2002). Modulation of T-lymphocyte development, growth and cell size by the Myc antagonist and transcriptional repressor Mad1. EMBO J 21: 4820-4830.
12. Kaadige MR, Yang J, Wilde BR, Ayer DE. (2015). MondoA-Mlx transcriptional activity is limited by mTOR-MondoA interaction. Mol Cell Biol 35: 101-110.
13. Louis CU, Shohet JM. (2015). Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med 66: 49-63.
14. Meyer N, Penn LZ. (2008). Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976-990.
15. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L, Evan GI. (2008). Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 14: 447-457.
16. O'Shea JM, Ayer DE. (2013). Coordination of nutrient availability and utilization by MAX-And MLX-centered transcription networks. Cold Spring Harb Perspect Med 3: a014258.
17. Palaskas N, Larson SM, Schultz N, Komisopoulou E, Wong J, Rohle D, Campos C, Yannuzzi N, Osborne JR, Linkov I, Kastenhuber ER, Taschereau R, Plaisier SB, Tran C, Heguy A, Wu H, Sander C, Phelps ME, Brennan C, Port E, Huse JT, Graeber TG, Mellinghoff IK. (2011). 18FFluorodeoxy-glucose positron emission tomography marks MYCoverexpressing human basal-like breast cancers. Cancer Res 71: 5164-5174.
18. Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, Rao A, Sheppard KE, Hugo W, Pupo GM, Pearson RB, Mcgee SL, Long GV, Scolyer RA, Rizos H, Lo RS, Cullinane C, Ayer DE, Ribas A, Johnstone RW, Hicks RJ, Mcarthur GA. (2014). Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov 4: 423-433.
19. Peterson CW, Ayer DE. (2011). An extended Myc network contributes to glucose homeostasis in cancer and diabetes. Front Biosci (Landmark Ed) 16: 2206-2223.
20. Peterson CW, Stoltzman CA, Sighinolfi MP, Han KS, Ayer DE. (2010). Glucose controls nuclear accumulation, promoter binding, and transcriptional activity of the MondoA-Mlx heterodimer. Mol Cell Biol 30: 2887-2895.
21. Shen L, O'Shea JM, Kaadige MR, Cunha S, Wilde BR, Cohen AL, Welm AL, Ayer DE. (2015). Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proc Natl Acad Sci USA 112: 5425-5430.
22. Shin D, Jeon JH, Jeong M, Suh HW, Kim S, Kim HC, Moon OS, Kim YS, Chung JW, Yoon SR, Kim WH, Choi I. (2008). VDUP1 mediates nuclear export of HIF1alpha via CRM1-dependent pathway. Biochim Biophys Acta 1783: 838-848.
23. Slack GW, Gascoyne RD. (2011). MYC and aggressive B-cell lymphomas. Adv Anat Pathol 18: 219-228.
24. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A, Hu M, Chan DA, Ethier SP, Van'T Veer LJ, Polyak K, Mccormick F, Gray JW. (2013). Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 24: 450-465.
25. Turner N, Moretti E, Siclari O, Migliaccio I, Santarpia L, D'incalci M, Piccolo S, Veronesi A, Zambelli A, Del Sal G, Di Leo A. (2013). Targeting triple negative breast cancer: is p53 the answer? Cancer Treat Rev 39: 541-550.
26. Walz S, Lorenzin F, Morton J, Wiese KE, Von Eyss B, Herold S, Rycak L, Dumay-Odelot H, Karim S, Bartkuhn M, Roels F, Wustefeld T, Fischer M, Teichmann M, Zender L, Wei CL, Sansom O, Wolf E, Eilers M. (2014). Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature 511: 483-487.
27. Wernicke CM, Richter GH, Beinvogl BC, Plehm S, Schlitter AM, Bandapalli OR, Prazeres Da Costa O, Hattenhorst UE, Volkmer I, Staege MS, Esposito I, Burdach S, Grunewald TG. (2012). MondoA is highly overexpressed in acute lymphoblastic leukemia cells and modulates their metabolism, differentiation and survival. Leuk Res 36: 1185-1192.
28. Wu N, Zheng B, Shaywitz A, Dagon Y, Tower C, Bellinger G, Shen CH, Wen J, Asara J, Mcgraw TE, Kahn BB, Cantley LC. (2013). AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol Cell 49: 1167-1175.
29. Yu FX, Chai TF, He H, Hagen T, Luo Y. (2010). Thioredoxin-interacting protein (Txnip) gene expression: sensing oxidative phosphorylation status and glycolytic rate. J Biol Chem 285: 25822-25830.